<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>CCI approves acquisition of Bharat Serums and Vaccines Limited by Mankind Pharma Ltd.</title>
    <link>https://www.taxtmi.com/news?id=27959</link>
    <description>Competition approval granted for Mankind Pharma Ltd.&#039;s acquisition of 100% shareholding in Bharat Serums and Vaccines Limited; a detailed order will follow. Mankind supplies finished dosage formulations and consumer healthcare products and, via subsidiaries, manufactures APIs and related inputs. BSV and its subsidiaries operate in FDFs, APIs, biotech and biological formulations, supplements, medical devices and ayurvedic medicines, with therapeutic focus on women&#039;s health, in vitro fertilisation and critical care. The transaction raises product and therapeutic area overlaps relevant to the Commission&#039;s merger assessment.</description>
    <language>en-us</language>
    <pubDate>Thu, 03 Oct 2024 09:39:10 +0530</pubDate>
    <lastBuildDate>Thu, 03 Oct 2024 09:39:10 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=771554" rel="self" type="application/rss+xml"/>
    <item>
      <title>CCI approves acquisition of Bharat Serums and Vaccines Limited by Mankind Pharma Ltd.</title>
      <link>https://www.taxtmi.com/news?id=27959</link>
      <description>Competition approval granted for Mankind Pharma Ltd.&#039;s acquisition of 100% shareholding in Bharat Serums and Vaccines Limited; a detailed order will follow. Mankind supplies finished dosage formulations and consumer healthcare products and, via subsidiaries, manufactures APIs and related inputs. BSV and its subsidiaries operate in FDFs, APIs, biotech and biological formulations, supplements, medical devices and ayurvedic medicines, with therapeutic focus on women&#039;s health, in vitro fertilisation and critical care. The transaction raises product and therapeutic area overlaps relevant to the Commission&#039;s merger assessment.</description>
      <category>News</category>
      <law>-</law>
      <pubDate>Thu, 03 Oct 2024 09:39:10 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/news?id=27959</guid>
    </item>
  </channel>
</rss>